PDS Biotechnology Corporation
PDSB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 1.28 | -0.08 | 0.47 |
| FCF Yield | -59.00% | -21.87% | -6.81% | -6.02% |
| EV / EBITDA | -1.17 | -3.02 | -8.03 | -6.65 |
| Quality | ||||
| ROIC | -86.94% | -83.39% | -60.00% | -26.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.93 | 0.78 | 0.63 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -4.23% | -30.83% | -105.91% | 5.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.59 | 0.82 | 1.24 | 3.02 |
| Interest Coverage | -7.77 | -10.23 | -31.64 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -10,285.44 | -44,460.29 | 0.00 | 0.00 |